Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-AT in Children With Autism
NCT00881452Phase 3Completed
- Sponsor
- Curemark
- Start
- May 2009
- Primary completion
- Jun 2011
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing CM-AT with Placebo (2 arms). Primary endpoint: Evidence of changes in behavior scales associated with the core symptoms of autism at 90 days. Started May 2009; status: completed.
02
Drugs
CM-AT
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00881452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881452.